Revitalizing Sexual Function in Heart Failure patients: The Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Erectile Dysfunction

Basit Öğe Kaydı
dc.authoridERBAY, ILKE/0000-0002-6817-4686
dc.contributor.authorErbay, Ilke
dc.contributor.authorAkin, Yesim
dc.date.accessioned2024-09-29T16:08:30Z
dc.date.available2024-09-29T16:08:30Z
dc.date.issued2024
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBACKGROUND/AIMS: The prognosis of heart failure (HF) is closely related to the structural integrity of the endothelium. Endothelial dysfunction is observed as a characteristic feature of HF and it plays an important role in the development of erectile dysfunction (ED) in patients with HF. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have been shown to increase microvascular endothelial cell function through their pleiotropic effects. Therefore, we aimed to investigate the effects of SGLT-2i treatment on ED in patients with HF. MATERIALS AND METHODS: Forty sexually active HF patients with reduced left ventricular ejection fraction [(LVEF) <40%] and ED were enrolled in this study. In all patients, their functional status was assessed according to the New York Heart Association functional classification, and erectile function was assessed by the Sexual Health Inventory for Men (SHIM) questionnaire at baseline and after three months of SGLT-2i treatment. RESULTS: SGLT-2i treatment resulted in a significant improvement in the SHIM scores (12.7 +/- 5.6 vs. 15.4 +/- 5.5, p<0.001). Predictors of improved SHIM scores with SGLT-2i were assessed using multivariable regression. Age (p=0.002), baseline SHIM scores (p=0.042), and lower extremity peripheral vascular disease (p=0.002) were identified as negative predictors of improvements in SHIM scores, while changes in brain natriuretic peptide levels (p=0.035) emerged as a significant predictor of improvement in SHIM scores. CONCLUSION: This cross-sectional study suggests that treatment by SGLT-2i could potentially provide advantages to patients with HF who also experience ED, enhancing their functional status.en_US
dc.identifier.doi10.4274/cjms.2024.2023-107
dc.identifier.endpage172en_US
dc.identifier.issn2149-7893
dc.identifier.issn2536-507X
dc.identifier.issue3en_US
dc.identifier.startpage167en_US
dc.identifier.urihttps://doi.org/10.4274/cjms.2024.2023-107
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7593
dc.identifier.volume9en_US
dc.identifier.wosWOS:001274070500003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofCyprus Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHeart failureen_US
dc.subjectSGLT-2 inhibitorsen_US
dc.subjectSHIM scoreen_US
dc.subjectsexual functionen_US
dc.subjectendothelial dysfunctionen_US
dc.titleRevitalizing Sexual Function in Heart Failure patients: The Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Erectile Dysfunctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu